Clinical Trial Update: Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of ARQ 092 in adults with advanced solid tumors and recurrent malignant lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Lymphoma
• Solid Tumor

Drugs mentioned

• ARQ 092 (ARQ-092)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Solid Tumor, Malignant Lymphoma | Phase 1 | Status: COMPLETED